Hepatitis A (HAV) Infection Drug Development Pipeline Study, H2 2018
Hepatitis A (HAV) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Hepatitis A (HAV) Infection pipeline products.
DISEASE OVERVIEW
The disease is primarily transmitted from human-to-human through fecal-oral route and also through exposure to contaminated food. Primary symptoms include fever, fatigue, vomiting, stomach pain, dark colored urine and jaundice. Currently, two doses of hepatitis A vaccine are being administered to children to immune against Hepatitis-A infection.
Global Hepatitis A disease treatment market size is valued at $2 billion, primarily due to increasing prevalence and high treatment costs. An increasing trend in terms of incidences is driving a large number of pharmaceutical companies to invest their resources for Hepatitis A pipeline development.
Companies actively participating in Hepatitis-A pipeline product development include%li%Boryung Pharmaceuticals, Changchun Institute of Biological Products, Indian Immunologicals, PaxVax, Sinovac Biotech Ltd and Zydus Cadila.
REPORT DESCRIPTION
The Hepatitis A (HAV) Infection pipeline guide presents complete overview of drugs currently being developed for Hepatitis A (HAV) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Hepatitis A (HAV) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Hepatitis A (HAV) Infection pipeline candidates is included.
Major companies participating in therapeutic development of Hepatitis A (HAV) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Hepatitis A (HAV) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Hepatitis A (HAV) Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Hepatitis A (HAV) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF HEPATITIS A (HAV) INFECTION PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
The disease is primarily transmitted from human-to-human through fecal-oral route and also through exposure to contaminated food. Primary symptoms include fever, fatigue, vomiting, stomach pain, dark colored urine and jaundice. Currently, two doses of hepatitis A vaccine are being administered to children to immune against Hepatitis-A infection.
Global Hepatitis A disease treatment market size is valued at $2 billion, primarily due to increasing prevalence and high treatment costs. An increasing trend in terms of incidences is driving a large number of pharmaceutical companies to invest their resources for Hepatitis A pipeline development.
Companies actively participating in Hepatitis-A pipeline product development include%li%Boryung Pharmaceuticals, Changchun Institute of Biological Products, Indian Immunologicals, PaxVax, Sinovac Biotech Ltd and Zydus Cadila.
REPORT DESCRIPTION
The Hepatitis A (HAV) Infection pipeline guide presents complete overview of drugs currently being developed for Hepatitis A (HAV) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Hepatitis A (HAV) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Hepatitis A (HAV) Infection pipeline candidates is included.
Major companies participating in therapeutic development of Hepatitis A (HAV) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Hepatitis A (HAV) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Hepatitis A (HAV) Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Hepatitis A (HAV) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF HEPATITIS A (HAV) INFECTION PIPELINE REPORT INCLUDES
- Panorama of Hepatitis A (HAV) Infection pipeline markets including statistics on therapeutic drugs and companies involved
- Hepatitis A (HAV) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Hepatitis A (HAV) Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Hepatitis A (HAV) Infection pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Hepatitis A (HAV) Infection pipeline therapeutics
- Get clear understanding of the entire Hepatitis A (HAV) Infection pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Hepatitis A (HAV) Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Hepatitis A (HAV) Infection Pipeline include-
Number of Companies with Hepatitis A (HAV) Infection projects in pre-clinical Development-
Number of Companies with Hepatitis A (HAV) Infection projects in Clinical Development-
Hepatitis A (HAV) Infection Pipeline Companies based in Americas
Hepatitis A (HAV) Infection Pipeline Companies based in Europe
Hepatitis A (HAV) Infection Pipeline Companies based in Asia Pacific
Hepatitis A (HAV) Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Hepatitis A (HAV) Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Hepatitis A (HAV) Infection Pipeline Agents in Clinical Development stage
Hepatitis A (HAV) Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Hepatitis A (HAV) Infection Pipeline agents
II. INSIGHTS INTO HEPATITIS A (HAV) INFECTION PIPELINE
1. Disease Overview
Introduction to Hepatitis A (HAV) Infection
Symptoms and Causes of Hepatitis A (HAV) Infection
Treatment or Prevention Options for Hepatitis A (HAV) Infection
Other Details
2. Phase wise Pipeline Compounds
Hepatitis A (HAV) Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Hepatitis A (HAV) Infection Pipeline- Phase 1 stage Drugs
Hepatitis A (HAV) Infection Pipeline- Phase 2 stage Drugs
Hepatitis A (HAV) Infection Pipeline- Phase 3 stage Drugs
Hepatitis A (HAV) Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Hepatitis A (HAV) Infection Pipeline Compounds
4. Hepatitis A (HAV) Infection Pipeline by Mechanism of Action
III. HEPATITIS A (HAV) INFECTION PIPELINE COMPOUND DETAILS
BR8003
Hepatitis A Vaccine-cnbg
Hepatitis A vaccine inactivated
Hepatitis A vaccine-paxvax
Hepatitis A and B vaccine
Hepatitis A vaccine -cadila
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. HEPATITIS A (HAV) INFECTION PIPELINE COMPANY BRIEFS
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
Indian Immunologicals Ltd
PaxVax Corporation
Sinovac Biotech Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL HEPATITIS A (HAV) INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Hepatitis A (HAV) Infection Pipeline include-
Number of Companies with Hepatitis A (HAV) Infection projects in pre-clinical Development-
Number of Companies with Hepatitis A (HAV) Infection projects in Clinical Development-
Hepatitis A (HAV) Infection Pipeline Companies based in Americas
Hepatitis A (HAV) Infection Pipeline Companies based in Europe
Hepatitis A (HAV) Infection Pipeline Companies based in Asia Pacific
Hepatitis A (HAV) Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Hepatitis A (HAV) Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Hepatitis A (HAV) Infection Pipeline Agents in Clinical Development stage
Hepatitis A (HAV) Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Hepatitis A (HAV) Infection Pipeline agents
II. INSIGHTS INTO HEPATITIS A (HAV) INFECTION PIPELINE
1. Disease Overview
Introduction to Hepatitis A (HAV) Infection
Symptoms and Causes of Hepatitis A (HAV) Infection
Treatment or Prevention Options for Hepatitis A (HAV) Infection
Other Details
2. Phase wise Pipeline Compounds
Hepatitis A (HAV) Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Hepatitis A (HAV) Infection Pipeline- Phase 1 stage Drugs
Hepatitis A (HAV) Infection Pipeline- Phase 2 stage Drugs
Hepatitis A (HAV) Infection Pipeline- Phase 3 stage Drugs
Hepatitis A (HAV) Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Hepatitis A (HAV) Infection Pipeline Compounds
4. Hepatitis A (HAV) Infection Pipeline by Mechanism of Action
III. HEPATITIS A (HAV) INFECTION PIPELINE COMPOUND DETAILS
BR8003
Hepatitis A Vaccine-cnbg
Hepatitis A vaccine inactivated
Hepatitis A vaccine-paxvax
Hepatitis A and B vaccine
Hepatitis A vaccine -cadila
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. HEPATITIS A (HAV) INFECTION PIPELINE COMPANY BRIEFS
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
Indian Immunologicals Ltd
PaxVax Corporation
Sinovac Biotech Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL HEPATITIS A (HAV) INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
